G-CSF Polyclonal Antibody, PeproTech®, Invitrogen™

Description

• AA Sequence of recombinant protein: TPLGPASSLP QSFLLKCLEQ VRKIQGDGAA LQEKLCATYK LCHPEELVLL GHSLGIPWAP LSSCPSQALQ LAGCLSQLHS GLFLYQGLLQ ALEGISPELG PTLDTLQLDV ADFATTIWQQ MEELGMAPAL QPTQGAMPAF ASAFQRRAGG VLVASHLQSF LEVSYRVLRH LAQP
• Preparation: Produced from sera of rabbits immunized with highly pure Recombinant Human G-CSF
• Anti-Human G-CSF-specific antibody was purified by affinity chromatography employing an immobilized Human G-CSF matrix
• Sandwich ELISA: To detect Human G-CSF by sandwich ELISA (using 100 μL/well antibody solution) a concentration of 0.5-2.0 μg/mL of this antibody is required
• This antigen affinity purified antibody, in conjunction with PeproTech Biotinylated Anti-Human G-CSF (500-P43Bt) as a detection antibody, allows the detection of at least 0.2-0.4 ng/well of Recombinant Human G-CSF
• Western Blot: To detect hG-CSF by Western Blot analysis this antibody can be used at a concentration of 0.1-0.2 μg/mL
• Used in conjunction with compatible secondary reagents the detection limit for Recombinant hG-CSF is 1.5-3.0 ng/lane, under either reducing or non-reducing conditions
• G-CSF (Granulocyte colony stimulating factor) is a naturally occurring cytokine that stimulates the production and antibacterial function of neutrophils and monocytes
• Human G-CSF is an 18.8 kDa protein containing 175 amino acid residues, and a soluble isoform of the G-CSF receptor has been described
• The pleotropic cytokine is produced by activated monocytes, macrophages, endothelial cells, fibroblasts, astrocytes, osteoblasts and bone marrow cells
• G-CSF has been shown to have specific effects on the proliferation, differentiation and activation of hematopoietic cells
• G-CSF is also expressed by various transformed cells such as carcinoma cells and myeloblastic leukemia cells
• G-CSF is encoded by two distinct DNA sequences, resulting in a full size, high activity and a shorter, low activity isoform of G-CSF
• G-CSF is highly conserved among species and has been shown to exert its biological functions through interaction with its receptor expressed on the surface of hematopoietic progenitors, neutrophilic granulocytes and certain carcinoma cell lines
• Clinical use of G-CSF has been approved for several therapeutic applications, treatment of neonatal infections, therapy of acute myocardial infarction, granulocyte transfusion in patients with neutropenia, in severe infections and sepsis, therapy in chronic autoimmune neutropenia, treatment of acute myeloid leukemias, Sweet's syndrome and AIDS
• Further, G-CSF has been shown to be a marker protein for different carcinomas such as bladder cancer and dysfunction of the protein has been linked to Kostmann Syndrome.